The NHS could be set for another shift in how patients access new technology, after NICE said the first topics under its new National HealthTech Access Programme would include capsule sponge tests for detecting oesophageal cancer and AI tools for identifying prostate and breast cancer. The programme was launched to speed access to selected high-impact technologies across England and Wales, with the aim of improving care and unlocking capacity in the health service. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
Early diagnosis tools move to the front of the queue
NICE said the new programme will expand its Technology Appraisals work to cover health technologies in a way similar to medicines, allowing a small number of selected technologies to be reimbursed and made available across the health service. The first two topics point to a clear emphasis on earlier diagnosis, with capsule sponge tests aimed at detecting oesophageal cancer and AI tools designed to identify prostate and breast cancer. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
The move follows broader changes in how NICE and the wider system are trying to shorten the path from evaluation to routine use. In March, NICE and the MHRA announced an aligned pathway that should help bring medicines to patients 3 to 6 months faster, while an improved Integrated Scientific Advice service was also introduced to give companies greater certainty in planning. ([nice.org.uk](https://www.nice.org.uk/news/articles/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process?utm_source=openai))
What the programme means for the NHS
According to NICE, the National HealthTech Access Programme is a collaborative approach involving NICE, the Department of Health and Social Care, NHS England, the MHRA and the Office for Life Sciences. The agency said it was designed to tackle the long-standing problem that cutting-edge health technology is often not widely used in the NHS, or is only available in some parts of the country. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
That ambition fits with other recent NICE guidance aimed at making care more efficient and more patient-centred. In May, NICE updated neonatal infection guidance so some babies could switch to oral antibiotics and continue treatment at home if they were doing well and responding to treatment, a change it said could reduce hospital stays and free up neonatal beds. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-updates-neonatal-infection-guidance-to-allow-home-antibiotic-treatment-for-some-babies?utm_source=openai))
For clinicians and patients, the latest step suggests that diagnostics and digital tools will continue to play a larger role in routine care if they meet evidential and cost-effectiveness standards. NICE has not said that every new technology will be adopted, but the programme indicates that selected innovations with the strongest potential impact are being moved through the system more quickly. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
In a health service under pressure to do more with limited resources, the direction is clear: faster access to the right tools, earlier diagnosis where possible, and greater use of technology to improve the way care is delivered across the NHS. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
